Similarly, Tokito et al. showed that in patients with stage II NSCLC treated with concurrent chemo-radiotherapy patients with positive PD-L1 expression tended to have poorer overall survival [311]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.